# Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid Tumors

> **NCT06022289** · PHASE2 · UNKNOWN · sponsor: **Tianjin Medical University Second Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Solid Tumor
- FGF Receptor Gene Mutation
- FGF Amplification
- FGF Receptor Gene Family Rearrangement
- FGF Receptor Gene Translocation

## Interventions

- **DRUG:** Pemigatinib

## Key facts

- **NCT ID:** NCT06022289
- **Lead sponsor:** Tianjin Medical University Second Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-01
- **Primary completion:** 2025-05-01
- **Final completion:** 2025-05-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06022289

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06022289, "Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06022289. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*